Development

Basal forebrain volumes predict circuit specific functional sensitivity to the muscarinic M1 receptor antagonist biperiden on cognition

By Geor Bakker, PhD, Pradeep Nathan PhD, Alex Godwood MSc. | Apr 3, 2019

We recently attended the Alzheimer’s & Parkinson’s Diseases (ADPD) Conference on 29th March in Lisbon, Portugal where we presented data in the session “Huntington’s and Other Neurodegenerative Diseases: Imaging, Biomarkers, Diagnostics”. In a collaboration led by Sosei Heptares, with the Amsterdam University Medical Centres and Maastricht University, we presented our novel findings in a poster showing that the basal forebrain nuclei volumes can sensitively predict circuitry specific effects of M1 receptor antagonist biperiden on cognition. This work forms an important part of the goals of the Neuroscience Experimental Medicine group to develop novel biomarkers that could define optimal treatment response as well as support patient stratification into clinical trials for drugs in development at Sosei Heptares

Drug Discovery

Trends and Innovation in Drug Discovery at Sosei Heptares

By Matt Barnes, Lisa Stott, David Tippet | Jan 9, 2019

We recently attended the British Pharmacological Society’s Pharmacology 2018 meeting on December 18th – 20th in London where we made two presentations including: 1 – Oral presentation on our approach to studying GPCRs in immuno-oncology and 2 – Poster presentation detailing a technology evaluation examining binding assay techniques at the histamine H4 receptor.

Development

Single and multiple dose safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers

By Pradeep Nathan | Dec 18, 2018

We attended the American College of Neuropsychopharmacology meeting on December 9-13, 2018 in Florida, U.S., and presented on the safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers.

Drug Discovery

New small molecule HTL0014242 shows early promise for slowing neurodegeneration

By Kirstie Bennett | Dec 9, 2018

Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield, UK working with scientists at Sosei Heptares have presented findings from preclinical studies investigating a new small molecule HTL0014242 in preclinical models of the neurodegenerative condition motor neurone disease (MND).

Corporate

Our Approach to Drug Discovery

By Sosei Heptares | Nov 28, 2018

An introduction to our unique and rationale approach to drug discovery which we hope will deliver new medicines for patients

Corporate

Introduction to Sosei Heptares

By Sosei Heptares | Nov 27, 2018

Sosei Heptares is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities.

Platform Technology

Structure-Based Drug Discovery of G protein-coupled receptors (GPCRs)

By Kirstie Bennett | Aug 29, 2018

We attended the 15th Meeting of the Asian-Pacific Society for Neurochemistry, held in August 27-29, 2018 in Macau, China. The presentation was focussed around our candidate compound HTL0014242 – a negative allosteric modulator of the metabotropic glutamate 5 receptor (mGlu₅). We presented the development of HTL0014242 from hit generation, using a fragment screening approach, to some preliminary efficacy data in the SOD1^G93A mouse model of amyotrophic lateral sclerosis (also known as motor neurone disease); data generated through a Sosei Heptares-funded PhD student in Dr Richard Mead’s lab at the Sheffield Institute for Translational Neuroscience.

Platform Technology

Manipulation of allosteric mechanisms in GPCR drug design

By Stacey Southall | Aug 3, 2018

We attended "Structure and Mechanism of Membrane Proteins", a Biochemical Society meeting on August 2-3, 2018 at Maple House in Birmingham UK, and presented recent case studies of allosteric modulators of GPCRs where Sosei Heptares StaR technology has enabled structural and biophysical characterisation of allosteric binding pockets and the mode of modulation on GPCRs. We explain how understanding of this diverse range of sites and mechanisms opens new avenues in SBDD towards generation of GPCR targeted drugs with improved therapeutic profile.

Platform Technology

Beyond the Happy Water

By Ben Tehan | Apr 11, 2018

We presented our research on water molecules and recent advances in the quantification of their contributions at "Structure-Activity Relationships".